The pandemic has certainly affected many aspects of life, but what about the medtech industry? Specifically for this audience, did COVID impact medtech investment strategy? As part of the recent Medtech MVP conference, host Geoff Pardo moderated a panel interview with four medtech investors to tackle that question and many more: Carter McNabb, Managing Director, River Cities Capital Funds; Darshana Zaveri, Managing Partner, Catalyst Health Ventures; Justin Klein, MD, JD, Co-Founder & Managing Partner, Vensana Capital; and Tara Butler, MD, Managing Director, Ascension Ventures. The panel also discussed aspects of the virtual world that are likely to remain in the entrepreneur/VC ecosystem, the latest drama around coverage and MCIT, the rise of consumerism and patient payment, the funding gap for early-stage companies, and the investment appetite for AI/data-driven diagnostics and devices. Listen now to catch these valuable insights!Panelists:Carter McNabb, Managing Director, River Cities Capital FundsDarshana Zaveri, Managing Partner, Catalyst Health VenturesJustin Klein, MD, JD, Co-Founder & Managing Partner, Vensana CapitalTara Butler, MD, Managing Director, Ascension Ventures

Medtech Talk

Episode 163: Venture Investing in a Post-COVID World

Bernie Haffey started his career as a high school physics teacher, then decided to go to business school. He remained interested in science and technology though, so he started working in the medtech industry at Hewlett-Packard’s Medical Products Group before transferring to Mentor Corp. After rising in the ranks at Mentor, Bernie then joined Summit Technology, where he was first exposed to the concept of high-performance management systems. He learned about the importance of a clear vision (and vision statement), the value of a mission statement and how it differs from a vision, and the benefit of narrowing a multitude of initiatives down to the vital few that focus on true breakthrough opportunities. After over two decades of experience as a senior leader at Summit, Intralase, NDO Surgical, and Nexis Vision, Bernie decided to return to his roots, found a consulting firm focused on high-performance management systems, and start teaching management science. In this interview with host Geoff Pardo, Bernie shares many of the critical aspects, decision points, and challenges of high-performance management systems, including how to balance voices of the customer, shareholder, and employee; the importance of a strong operational team who can carry out a new vision; the need for effective systems in addition to brilliant staff; and many of the watchouts when leading change in an organization.

Episode 162: Bernie Haffey on Cutting Through to High Performance

Now a seasoned medtech entrepreneur and leader, Amar Sawhney first became interested in the industry starting in graduate school. He was studying chemical engineering and developing biodegradable polymers for adhesion prevention and hydrogels for light-activated polymerization within the body. He and his advisor were then approached by Mayfield Fund to spin out the technology into the startup Focal. Amar was fortunate to learn a lot from then CEO Mark Levin, including some hard lessons that drove him and Fred Khosravi to found Incept, an IP holding company for creating operating companies based on field of use. As CEO/Founder of Confluent Surgical, AccessClosure, Augmenix, Ocular Therapeutix, and now Instylla, Amar learned how to transition from scientist to executive and is truly a medtech influencer. In this interview with host Geoff Pardo, Amar shares many of the valuable lessons he’s learned founding and managing various startups, including how to find the right application for a technology, when a platform solution really makes sense, how to effectively lead and build successful teams, the value of a diverse workforce, and tips for overcoming the funding gap for early-stage companies, plus his candid thoughts on the differences in funding/entrepreneurship between the East and West coasts.Amarpreet (Amar) Sawhney, Ph.D., is the Founder, Chief Executive Officer and Chairman of the Board of Directors of Instylla. He is also the CEO of Pramand LLC, and Rejoni, Inc. Prior to this Dr. Sawhney served as CEO and Chairman of Augmenix (acquired by Boston Scientific) and Ocular Therapeutix (NASDAQ: OCUL). In addition, he is a general partner of Incept, LLC, an intellectual property holding company. Previously, Dr. Sawhney founded Confluent Surgical and served as its President and CEO prior to its acquisition by Covidien plc. He also was a technology founder of Focal, Inc., a biopharmaceutical company acquired by Genzyme Corporation, and a founder of AccessClosure, Inc., acquired by Cardinal Health. Dr. Sawhney’s innovations are the subject of over 120 issued and pending patents. He holds M.S. and Ph.D. degrees in chemical engineering from the University of Texas at Austin, as well as a B.Tech. in chemical engineering from the Indian Institute of Technology, Delhi India.

Episode 161: Amar Sawhney on Finding the Right Chemistry for Entrepreneurial Success

Navigating the ever-changing sea of medtech reimbursement is never easy, particularly with the recent swings in policies pertaining to breakthrough devices. As part of the continued Medtech Talk Digital Discussion Series, host Geoff Pardo moderates a panel interview with three medtech reimbursement experts to look at strategies for obtaining reimbursement coding, coverage, and payment: Mary Hailey, CCM, CDMS, Vice President Health Economics and Reimbursement, Relievant Medsystems, Inc.; DeChane Dorsey, JD, Executive Director of AdvaMed Accel, AdvaMed; and David Gregory, Principal, Healthcare & Life Sciences Consulting Leader, Baker Tilly. The panel discusses coding and payment issues that are particularly pertinent to small/mid-sized companies; the impact of recent changes to accommodate breakthrough devices, including MCIT, Add-On payment, NTAP, and TPT; CMS’s approach to handling issues/questions and how to best work with the agency; thinking wholistically about bringing your product to market (more than just FDA approval); and the influence of advocacy efforts by physician specialty societies on coding and payments. Listen now to catch these valuable insights!Mary Hailey, CCM, CDMS, Vice President Health Economics and Reimbursement, Relievant Medsystems, Inc. DeChane Dorsey, JD, Executive Director of AdvaMed Accel, AdvaMed David Gregory, Principal, Healthcare & Life Sciences Consulting Leader, Baker Tilly

Episode 160: Securing Coverage and Payment for Your Innovative Medical Device: Advice from the Experts

There’s nothing like those pivotal moments of a startup that lead to it becoming wildly successful. The excitement as the company’s first product begins to earn market share and attention from additional investors or acquirers. This month’s podcast guest Joe Mandato has been in that situation with several successful startups turned corporations, including Guidant Corporation, Origin Medical Systems (predecessor of Intuitive Surgical), and Align Technology (maker of InvisAlign), as well as leading Tear Science and iOptics Research. Joe has learned a lot about leadership throughout these endeavors and his doctoral research on the effectiveness of corporate governance. He’s seen firsthand the importance of understanding where leaders can contribute and where they need help; switching from the “wrong” application to the “right” one; having technological innovation at root, but the right business model innovation and culture to achieve to success; and maximizing boards of directors. After many decades in the industry, Joe is truly a medtech mentor. In this interview with host Geoff Pardo, Joe shares many of the valuable lessons he’s learned working with various startups, how to shift from being an operator to an investor, how to best leverage boards and board meetings, and his suggestions for changes in the healthcare system and opportunities coming out of COVID.Joe Mandato holds a Doctor of Business Administration degree from Case Western Reserve University, where his research focused on the evolving role of boards in ensuring effective corporate governance. He was a 2011-2012 Fellow of Harvard University’s Advanced Leadership Initiative and served as Co-Chair of Harvard’s Advanced Leadership Coalition. He is a Managing Director at DeNovo Ventures, Senior Advisor at Apercen Partners and Sonder Capital and Lecturer at Stanford University. He has served on more than 20 public and private boards of directors focused on technology and the life sciences. He also serves on the boards of Case Western Reserve University, Headstart and Save the Children. He was an investor, board member and advisor to the founders of Align Technologies (Invisalign) and has served as CEO of five life sciences companies, which created significant shareholder value. He was a member of the founding management committee of Guidant Corporation (NYSE) and was an entrepreneur-in-residence at Mayfield Fund, a Silicon Valley venture fund. He has authored or co-authored numerous articles on healthcare and governance and the book The Entrepreneur’s Journey.

Episode 159: Lessons from Medtech Leader and Mentor Joe Mandato

Like many entrepreneurs, Christian Gormsen admits he didn’t start his career with a passion for his current field. Instead, he backed into the hearing industry from his work in investment banking and consulting, and eventually wound up working at the world&apos;s 4th largest hearing aid company. Christian realized just how stigmatized hearing aids are and became determined to address this. In 2012, he was first connected to Eargo while doing advisory work. Unlike other traditional hearing aids, Eargo’s products are basically invisible, comfortable, rechargeable, removable, and sold directly to consumers rather than via physicians. After being a board member for about 3 years, Christian was asked to lead Eargo as CEO through a challenging time in 2016, and by the end of 2017, he had achieved a four-fold increase in sales and the company has since gone public. In this interview with host Geoff Pardo, Christian shares his story of entering the hearing industry and then joining Eargo, various unique aspects about the company compared to traditional hearing aid manufacturers that have led to their success, achieving cognitive diversity via cultural diversity, and the effect on the company’s personnel after its recent transition to being public.

Episode 158: Now Hear This: Christian Gormsen on Breaking Convention in the Hearing Industry at Eargo

After passing out from extremely painful complex ovarian cists at age 13, Surbhi Sarna became all too familiar with the challenges and lack of adequate solutions for women’s health. Benefiting from intelligent and entrepreneurial parents, she became so determined to start a company to tackle women’s health issues someday that she wrote it in her college application personal statement. After graduating from UC Berkely, she went to Abbott Vascular to work on some of their most innovative products before transitioning to BioCardia for more of a startup culture. While at both places, she continued to read papers about women’s health, and after she lost her grandmother to breast cancer, she decided to take her leap of faith and start nVision Medical. In this interview with host Geoff Pardo, Surbhi shares her story of founding and leading nVision, including securing a very challenging first funding round, transitioning from being an engineer to a woman CEO, negotiating the company’s eventual exit, and staying onboard to support the product’s further development as part of Boston Scientific. Here all this plus Surbhi’s thoughts on the changing landscape of women’s health and what’s next for her.

Episode 157: Success nVisioned, Surbhi Sarna’s Story

Despite the pandemic, 2020 was a successful year for medtech. The industry reaped the fruits of over a decade of concerted effort to reduce regulatory hurdles, work better with hospitals and diagnostic companies, and increase innovation. As part of the continued Medtech Talk Digital Discussion Series, host Geoff Pardo teams up with Justin Klein to co-moderate a panel interview with three medtech investment experts to recap 2020 and look to strategies for 2021: Scott Whitaker, President and CEO, AdvaMed; Mark Deem, Venture Partner, Lightstone Ventures; Managing Partner, The Foundry, LLC; and Rachel Jonas, Vice President and Investment Analyst, T. Rowe Price. The panel discusses challenges, watchouts, and opportunities for 2021; the continually evolving reimbursement landscape; the need to and how to encourage more early stage investing; public funding and whether the medtech IPO window will persist; where to invest next; and what new administration and policy issues to watch out for. Listen now to catch these valuable insights!

Episode 156: How Medtech Can Sustain its Momentum in 2021: Strategies for Successful Investment

Inari Medical is a 2020 success story. The company was one of the first medtech companies to IPO during the pandemic. As part of the new Medtech Talk Digital Discussion Series, host Geoff Pardo had a chance to conduct a panel interview with four members of the Inari management team: Bill Hoffman, CEO; Drew Hykes, CCO; Thomas Tu, MD, CMO; and Tara Dunn, Vice President of Clinical Affairs and Market Development. The team discussed their unique culture, strong mission, early success, sales strategy and many other topics, including advice from Bill to other entrepreneurs who are considering going public, reflections from Tom on the transition from being a physician to the business world, benchmarking from Drew on how this experience compares to other ventures he has been in, and comparisons from Tara on the difference between working for a big company vs. a smaller company. Tune in now to hear from one of medtech’s most promising companies!

Episode 155: Inari Medical: Clot Warriors—Changing the Paradigm in DVT and Pulmonary Embolism

After an ill family member introduced Justin Barad to the world of healthcare, he decided to earn a bioengineering degree, then an MD, and eventually specialized in pediatric orthopaedics. However, Justin later opted to combine his surgical skills with his passion for software and gaming to take on a new challenge: the training of surgeons. He decided to switch from academic medicine and start Osso VR in 2016, and now the company has grown to over 60 employees serving 20 countries with over 70 procedures loaded on the platform. In this interview with host Geoff Pardo, Justin shares his view on the challenges of surgical training, how Osso VR’s virtual surgical training procedures can be used to both train and assess surgeons remotely, his transition from clinician to CEO, his experience fundraising as a new entrepreneur, and advice for other surgeons considering entrepreneurial endeavors.

Episode 154: Medtech Goes Virtual at Osso VR

After 20+ years as an academic physician, Karen Noblett was presented with a new opportunity: join Axonics as the company’s CMO. Originally, she was concerned about what her peers would think, as she had established a reputation of being ethically involved with industry and did not want to compromise that. Ultimately, she decided this presented a pathway to improving patient treatments and outcomes on a broader scale, so she accepted the position and has enjoyed the experience ever since. From helping the team build the final product to overseeing clinical trials to experiencing an IPO and finally to a successful commercial launch, Karen learned a great deal about the medical device industry. In this interview with host Geoff Pardo, Karen shares informative background on the physiology of overactive bladder and the various treatments available, including Axonic’s sacral neuromodulation device (a so called “bladder pacemaker”); recounts her transition from academia to industry; and reflects on some of her most influential mentors and how they affected her own leadership style.

Episode 153: Stimulating Confidence by Solving Incontinence

Jon Bloom admits that his path to becoming a CEO was anything but linear. Originally a percussionist, Jon then found a calling for medicine and became a board-certified physician before pivoting once more to entrepreneurship. Now holding the reigns at Podimetrics, a company developing an early warning system for diabetic foot ulcers, Jon shares not only his unique career progression, but the story of how a hackathon led to the company’s inception, when to commercialize a new technology, tips for working the VA, and the revolution of telehealth during this current time.

Episode 152: Stomping out Diabetic Foot Ulcers at Podimetrics

From senior leadership positions at GE Healthcare and Medtronic to board chairman at MDIC and AdvaMed, Nadim is a seasoned medtech executive who is passionate about the industry. Now at the helm of CVRx, a company developing a pioneering technology for treating high blood pressure and heart failure, Nadim shares his experience navigating the FDA’s first Breakthrough Device Designation, working with CMS on reimbursement coding, and building CVRx’s strong leadership team

Episode 151: Breaking Through at CVRx

Katie Szyman is an accomplished global operating executive in the medical device industry with a passion for building high performing teams and helping innovative healthcare companies grow so patients can gain access to better therapies and outcomes. Here she shares how Edwards, critical care, and the medtech industry is adapting to COVID19, her leadership role models, and tips for expanding diversity on leadership teams and executive boards.

Episode 150: Edwards' Katie Szyman on Medtech's Accelerating Changes, Leadership Development and Having Fun

Mike Huggins is a leader in the medtech world whose journey from Synthes, USA COO to an indictment and prison sentence has run parallel to his discovery of yoga, mindfulness, and meditation, weaving together these experiences that have developed his passion for ethical leadership, corporate responsibility, prison reform, and the practices that have helped him along the way. 

Episode 149: Ethical Leadership, Corporate Responsibility, and the Transformative Power of Yoga

A weekly conversation with the innovators who will change how health care is delivered.

hubhopper

Medtech Talk

hubhopper